

BIOLOGICAL DRUGS FOR THE TREATMENT OF MODERATE-TO-SEVERE PLAQUE PSORIASIS: ANALYSIS ACCORDING TO THE MECHANISM OF ACTION

ATC code: L04
IMMUNOSUPPRESSIVE AGENTS

ABSTRACT NUMBER:
4CPS-328

Ilaria SOLAZZI, Maria Francesca GUIDI, Paolo ABRATE, Elena Caterina ZINETTI
ASL TO4 - Hospital Pharmacy - Ciriè, Chivasso e Ivrea (TO) - ITALY



Email contact: ilasol89@libero.it

WHAT WAS DONE

We aim to describe the population of outpatients treated with biological drugs for moderate-to-severe plaque psoriasis according to the number and the type of therapeutical shifts.

WHY WAS DONE

In the last years many biological drugs have been approved for the treatment of moderate-to-severe plaque psoriasis.

HOW IT WAS DONE

We identified patients treated with a biological drug for moderate-to-severe plaque psoriasis (code ICD-9-CM "696.1 other psoriasis") from February 2017 to September 2020.

Data were collected from drug refills by our pharmacy – electronically recorded.

MECHANISM OF ACTION	BIOLOGICAL DRUGS
ANTI TNF-ALFA	ADALIMUMAB, CERTOLIZUMAB, ETANERCEPT
ANTI IL-17	BRODALUMAB, IXEKIZUMAB, SECUKINUMAB
ANTI IL-23	GUSELKUMAB, RISANKIZUMAB, TILDRAKIZUMAB, USTEKINUMAB

The therapeutical shift was intended as a change in the active substance, regardless of changes from an originator to its biosimilar/s, the pharmaceutical form (pen or syringe) or the dose.

WHAT WAS ACHIEVED


357 patients	Median age: 50.7 years (range 5.9 to 91.7)	Male patients: 221 (61.9%)
--------------	--	----------------------------

ONLY ONE BIOLOGICAL DRUG

TWO BIOLOGICAL DRUGS IN SEQUENCE

THREE BIOLOGICAL DRUGS

FOUR BIOLOGICAL DRUGS



Many different sequence combinations

MORE THAN 97% OF PATIENTS WERE TREATED WITH ONLY ONE (79%) OR TWO (18.2%) BIOLOGICAL DRUGS WITH A PREVALENCE OF ANTI IL-17.

NUMBER OF PATIENTS	FROM	TO
3	Anti TNF-alfa	Anti TNF-alfa
31	Anti TNF-alfa	Anti IL-17
5	Anti TNF-alfa	Anti IL-23
3	Anti IL-17	Anti TNF-alfa
8	Anti IL-17	Anti IL-17
3	Anti IL-17	Anti IL-23
2	Anti IL-23	Anti TNF-alfa
7	Anti IL-23	Anti IL-17
3	Anti IL-23	Anti IL-23

WHAT IS NEXT

We have to further investigate the causes for the change from one to another biological drug. These could include adverse events, ineffectiveness or other reasons.